At Anavex, we thrive on the benefits of collaboration and teamwork as we work to identify potential breakthroughs in the central nervous system. The strength and resilience of patients and their families inspire us to translate breakthroughs into therapeutics. Our vision of transforming people’s lives through science is made possible by the talent and passion of our workforce, each bringing unique skills and insights.

Community-based partnerships guide our pre-clinical and clinical research to ensure we do not impose unnecessary burden on the people we aim to serve. As a science-driven company, we know it is through diversity of thought and community-based collaborations that we can address the disease areas where people are still waiting for treatments.

From the youngest person living with Rett syndrome or Fragile X syndrome to the oldest person experiencing Alzheimer’s disease or Parkinson’s disease dementia, our vision as a company is only made possible if patients have equitable access to healthcare. We recognize that we have a role to play in addressing health equity across the healthcare institutional continuum.

A Global Burden of Disease study shows that Alzheimer’s disease and other dementias are among the 3 most burdensome neurological disorders in the U.S. CNS disorders impact a large number of people with a variety of different cultures and personal backgrounds. From infants to the elderly, we are dedicated to addressing the devastating impact of neurological disorders through our proprietary SIGMACEPTOR™ development platform.

A large body of evidence indicates that autophagy restoration through sigma-1 receptor (SIGMAR1) activation is an important drug target for a number of neurological disorders. SIGMAR1 is enriched in the central nervous system (CNS) and is the target for the orally available blarcamesine (ANAVEX^®2-73) and ANAVEX^®3-71.

We are proud of the journey we have initiated and look forward to continuing the work required to achieve life-saving therapeutic discovery goals.